USFDA completes Pre-Approval Inspection at FTO-9 Visakhapatnam; Form 483 with three observations issued
USFDA completed a Pre-Approval Inspection (PAI) at the company's FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh.
By ScoutQuest · · 2 min read
- Inspection dates
- October 8, 2026, to October 9, 2026
- Inspection outcome
- Form 483 with three observations
- Facility inspected
- FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh
What the company disclosed
The company has informed the exchanges that the United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh.
- Inspection dates: October 8, 2026, to October 9, 2026
- Outcome: a Form 483 with three observations
- Company's stated next step: address the observations within the stipulated timeline
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What a Pre-Approval Inspection is
A Pre-Approval Inspection is carried out by the USFDA in connection with a product approval application. The inspector checks whether the site can manufacture the product in line with the application and with applicable manufacturing practice requirements. It is linked to specific products under review.
What a Form 483 is
A Form 483 is the document in which an inspector records observations made at the end of an inspection. Receiving a Form 483 is not the same as a warning letter or an enforcement action. Companies typically send a written response to the observations, and the USFDA reviews that response.
How to read this
- The update states the number of observations — three — but the impact on the company would depend on what the observations relate to, which is not something the update describes.
- The company has said it will respond within the stipulated timeline, so the next visible step would be its response and any further communication from the USFDA.
- Form 483 observations can range widely in nature, from procedural matters to more substantive ones. Investors commonly track the company's follow-up disclosures on the same facility.
What stays unchanged as of this update
The update asks that the information be taken on record. It sets out the inspection dates, the number of observations, and the company's stated intention to respond within the stipulated timeline.
Also from Dr Reddys Laboratories
Dr Reddy's files audio and video recordings of October 23, 2026 earnings call on Q2/H1 FY27 results
24 Oct 2026
Auditor's limited review reports with UDIN on Q2 and H1 results
23 Oct 2026
Board approves appointment of Akhil Ravi as Head API and Services and Senior Management Personnel
23 Oct 2026
More numbers
- Observations in the USFDA Form 483three
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.